ABSTRACT
No disponible
Subject(s)
Humans , Osteoporosis/drug therapy , Anabolic Agents/therapeutic use , Receptor, IGF Type 1/metabolism , Growth Substances/metabolism , Human Growth Hormone/metabolism , Parathyroid Hormone/metabolismABSTRACT
No disponible
Subject(s)
Humans , Osteoporosis, Postmenopausal/diagnosis , Osteoporosis, Postmenopausal/therapy , Osteoporosis, Postmenopausal/prevention & control , Societies, Medical , SpainABSTRACT
Objetivo. Evaluar la evolución de diversos parámetros metabólicos en pacientes con enfermedad de Paget tratados con pamidronato por vía intravenosa en uno o dos ciclos. Pacientes y métodos. Catorce pacientes recibieron 15 mg/día de pamidronato durante cinco días. Se determinaron: fosfatasa alcalina total (FAT), fosfatasa ácida tartrato resistente (FATR), piridinolina (Pyr), vitamina D, hormona paratiroidea (PTH) y calcio iónico, al inicio, a la semana, al mes, a los tres y seis meses de tratamiento. Seis pacientes recibieron un segundo ciclo de tratamiento a los dos años del primero. Resultados. Se produjo una reducción de los parámetros de formación y resorción ósea, siendo significativa para la FAT a partir del tercer mes (p<=! 0,01), la FATR a los tres y seis meses (p <= 0,01) y la Pyr al mes y tres meses (p<=! 0,05). La PTH aumentó inicialmente, reduciéndose posteriormente junto con el calcio iónico. Con el segundo ciclo se comprobó un menor descenso de todos los parámetros bioquímicos, siendo sólo significativo el descenso de la FAT a los tres (p<= 0,01) y seis meses (<= 0,05). La PTH se mantuvo siempre por encima de los niveles basales y el calcio iónico se comportó como en el primer ciclo. Conclusiones. El pamidronato es un tratamiento efectivo y seguro en la enfermedad de Paget, que consigue una reducción de los marcadores del metabolismo óseo, si bien es menos marcada con ciclos sucesivos (AU)
Subject(s)
Aged , Female , Male , Humans , Osteitis Deformans/drug therapy , Diphosphonates/administration & dosage , Alkaline Phosphatase/blood , Acid Phosphatase/blood , Calcium Channels/blood , Vitamin D/blood , Injections, Intravenous , Parathyroid Hormone/bloodABSTRACT
Benign familial hyperphosphatasemia is a rare biochemical abnormality of hereditary nature, characterized by the presence of persistently elevated levels of serum alkaline phosphatase in several members of the same family, in the absence of disease or any known cause of hyperphosphatasemia. To date, there have been 29 pedigrees reported in the literature. Another two families affected with hyperphosphatasemia, originating in an increase in the bone isoenzyme, are described. The epidemiology, inheritance, isoenzymatic patterns, postulated mechanisms and clinical significance of this entity are discussed.
Subject(s)
Alkaline Phosphatase/blood , Family Health , Metabolism, Inborn Errors , Phosphorus Metabolism Disorders/genetics , Adult , Alkaline Phosphatase/metabolism , Female , Humans , Isoenzymes , Male , Middle Aged , Pedigree , Phosphorus Metabolism Disorders/epidemiology , Phosphorus Metabolism Disorders/pathologyABSTRACT
A prospective study of the capillaroscopy changes in 15 patients afflicted with vasculitis is presented. 2 of them had classic polyarteritis nodos (PAN), 3 had Churg-Strauss allergic angiitis and granulomatosis, 2 had hypersensitivity vasculitis (HV), 6 had giant-cell arteritis (GCA) and 2 had polyangiitis overlap syndrome (POS). Periungual capillaroscopy (PC) showed isolated changes in 11 patients (73%). We observed more changes in those cases with active disease (83% vs. 67%); they were mainly microhemorrhage (without any statistical significance). There were no more findings in patients with a more generalised affliction (nervous system, kidneys and/or skin) than in the others. In conclusion, the capillaroscopy findings were few and non-specific. PC is a diagnostic method of negligible value in this type of disease.
